Becker's Healthcare October 23, 2024
Alexandra Murphy

The FDA approved Pfizer’s Abrysvo, the first and only RSV vaccine for adults aged 18 to 59 who are at increased risk of severe respiratory illness caused by RSV.

The approval is based on data from Pfizer’s Phase 3 MONeT trial, which evaluated the vaccine’s safety and efficacy in high-risk adults, according to an Oct. 22 news release from...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Surgeon general says U.S. smoking rates have tumbled, but not for everyone
Research highlights disparities in heart disease, stroke trends worldwide
Suicide is NOT a Symptom: Healthcare Is Missing the Mark on Suicide Prevention
Community Pharmacies Hold Key Role in Protecting Older Adults From RSV
Study Finds Nearly 75% of Adults 25 and Older Have Overweight or Obesity

Share This Article